UK’s Leukaemia Therapeutics market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX.X% during the forecast period.
Leukaemia is the 12th most common cancer in the UK, accounting for 3% of all new cancer cases. In females in the UK, leukaemia is the 12th most common cancer, with around 4,000 new cases. In males in the UK, leukaemia is the 10th most common cancer, with around 5,800 new cases. Incidence rates for leukaemia in the UK are highest in people aged 85 to 89. Each year almost 4 in 10 (38%) of all new leukaemia cases in the UK are diagnosed in people aged 75 and over. Since the early 1990s, leukaemia incidence rates have increased by a sixth (17%) in the UK. Rates in females have increased by around a seventh (14%) and rates in males have increased by around a seventh (13%).
Market Driving and Restraining Factors
The market for Leukemia Therapeutics in UK is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and a growing number of biotechnology firms.
As Leukemia cases are more common in adults and are observed to progress with aging, the increase in geriatric population also plays its role in the market growth.
Factors like the high cost of drugs and treatments along with many entry-to-market barriers are the major restraining factors for this market.